NL301144I2 - Apalutamide - Google Patents

Apalutamide

Info

Publication number
NL301144I2
NL301144I2 NL301144C NL301144C NL301144I2 NL 301144 I2 NL301144 I2 NL 301144I2 NL 301144 C NL301144 C NL 301144C NL 301144 C NL301144 C NL 301144C NL 301144 I2 NL301144 I2 NL 301144I2
Authority
NL
Netherlands
Prior art keywords
apalutamide
Prior art date
Application number
NL301144C
Other languages
English (en)
Dutch (nl)
Original Assignee
Aragon Pharmaceuticals Inc
Sloan Kettering Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301144(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc, Sloan Kettering Inst Cancer Res filed Critical Aragon Pharmaceuticals Inc
Publication of NL301144I2 publication Critical patent/NL301144I2/nl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NL301144C 2012-06-07 2021-11-03 Apalutamide NL301144I2 (nl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07
PCT/US2013/044116 WO2013184681A1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator
EP13800681.2A EP2858985B1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator
EP18157435.1A EP3348553B1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Publications (1)

Publication Number Publication Date
NL301144I2 true NL301144I2 (nl) 2025-03-20

Family

ID=49712550

Family Applications (1)

Application Number Title Priority Date Filing Date
NL301144C NL301144I2 (nl) 2012-06-07 2021-11-03 Apalutamide

Country Status (45)

Country Link
US (9) US9481663B2 (enExample)
EP (4) EP3348553B1 (enExample)
JP (3) JP6182209B2 (enExample)
KR (2) KR102062024B1 (enExample)
CN (3) CN113135892A (enExample)
AU (3) AU2013271751B2 (enExample)
BR (1) BR112014030678A2 (enExample)
CA (4) CA3114726A1 (enExample)
CL (1) CL2014003331A1 (enExample)
CO (1) CO7240407A2 (enExample)
CR (2) CR20190331A (enExample)
CY (4) CY1120393T1 (enExample)
DK (3) DK3348553T3 (enExample)
EA (3) EA028791B1 (enExample)
EC (1) ECSP14030098A (enExample)
ES (3) ES2809738T3 (enExample)
FR (1) FR21C1050I2 (enExample)
GT (1) GT201400283A (enExample)
HK (2) HK1210175A1 (enExample)
HR (3) HRP20180902T1 (enExample)
HU (4) HUE038082T2 (enExample)
IL (5) IL320522A (enExample)
IN (1) IN2014DN10084A (enExample)
LT (4) LT3533792T (enExample)
LU (1) LUC00236I2 (enExample)
ME (2) ME03815B (enExample)
MX (1) MX356754B (enExample)
MY (1) MY187500A (enExample)
NI (1) NI201400142A (enExample)
NL (1) NL301144I2 (enExample)
NO (1) NO2021046I1 (enExample)
NZ (2) NZ702203A (enExample)
PE (3) PE20200725A1 (enExample)
PH (2) PH12014502714B1 (enExample)
PL (3) PL2858985T3 (enExample)
PT (3) PT2858985T (enExample)
RS (3) RS61988B1 (enExample)
SG (3) SG10201610249TA (enExample)
SI (3) SI3533792T1 (enExample)
SM (3) SMT201800311T1 (enExample)
TR (1) TR201808939T4 (enExample)
TW (1) TWI532732B (enExample)
UA (2) UA115665C2 (enExample)
WO (1) WO2013184681A1 (enExample)
ZA (1) ZA201500076B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
PE20150099A1 (es) 2011-12-16 2015-01-30 Olema Pharmaceuticals Inc Compuestos novedosos de benzopirano, composiciones y usos de los mismos
ES2809738T3 (es) 2012-06-07 2021-03-05 Aragon Pharmaceuticals Inc Formas cristalinas de un modulador de receptor de andrógenos
WO2014043208A1 (en) 2012-09-11 2014-03-20 Medivation Prostate Therapeutics, Inc. Formulations of enzalutamide
PT3305285T (pt) 2012-09-26 2020-11-24 Aragon Pharmaceuticals Inc Antiandrogénios para o tratamento de cancro da próstata resistente à castração não metastático
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CN106795152B (zh) * 2014-08-26 2020-01-31 安斯达尔生物技术有限责任公司 蛋白激酶抑制剂
CR20170217A (es) 2014-12-05 2017-08-30 Aragon Pharmaceuticals Inc Composiciones anticancerígenas
CA2969675C (en) 2014-12-05 2023-06-06 Aragon Pharmaceuticals, Inc. Anticancer compositions
BR112017011788A2 (pt) 2014-12-05 2017-12-26 Aragon Pharmaceuticals Inc composições anticâncer
WO2016100905A1 (en) 2014-12-19 2016-06-23 Lutron Electronics Co., Inc. Multi-channel lighting fixture having multiple light-emitting diode drivers
TW201808287A (zh) 2016-06-03 2018-03-16 美商艾瑞岡醫藥公司 抗癌組成物
ES2952770T3 (es) 2016-12-13 2023-11-06 Watson Lab Inc Formas de estado sólido de apalutamida
EP4438126A3 (en) 2017-10-16 2025-01-01 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019135254A1 (en) 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
WO2019242439A1 (zh) * 2018-06-20 2019-12-26 苏州科睿思制药有限公司 Arn-509的晶型及其制备方法和用途
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it) 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
EP4017848A1 (en) * 2019-08-22 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) * 2019-09-20 2019-12-20 武汉大学 一种阿帕鲁胺化合物及其药物制剂
WO2022049265A1 (en) 2020-09-04 2022-03-10 Synthon B.V. Improved process for preparation of apalutamide
CN112679468A (zh) * 2021-01-05 2021-04-20 四川科伦药物研究院有限公司 阿帕他胺的晶体形式、制备方法和用途
WO2023143090A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN116332907A (zh) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 一种无定形阿帕他胺的制备方法
WO2025153768A1 (en) * 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
PL3412290T3 (pl) 2006-03-27 2021-09-06 The Regents Of The University Of California Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
CA2648139A1 (en) * 2006-03-29 2007-11-08 The Regents Of The University Of California Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EA028869B1 (ru) 2010-02-16 2018-01-31 Арагон Фармасьютикалс, Инк. Модуляторы рецептора андрогенов и их применение
ES2809738T3 (es) 2012-06-07 2021-03-05 Aragon Pharmaceuticals Inc Formas cristalinas de un modulador de receptor de andrógenos
WO2019242439A1 (zh) 2018-06-20 2019-12-26 苏州科睿思制药有限公司 Arn-509的晶型及其制备方法和用途

Also Published As

Publication number Publication date
HUE054595T2 (hu) 2021-09-28
MY187500A (en) 2021-09-24
TW201402561A (zh) 2014-01-16
SI3348553T1 (sl) 2020-11-30
CA2875767A1 (en) 2013-12-12
RS61988B1 (sr) 2021-07-30
EA201492272A1 (ru) 2015-05-29
US20190241539A1 (en) 2019-08-08
IL267608A (en) 2019-08-29
PE20200795A1 (es) 2020-08-10
HUE038082T2 (hu) 2018-09-28
US12018008B2 (en) 2024-06-25
RS60617B1 (sr) 2020-09-30
MX356754B (es) 2018-06-11
EP3533792A1 (en) 2019-09-04
PE20200725A1 (es) 2020-07-21
KR102195916B1 (ko) 2020-12-30
MX2014015005A (es) 2015-09-04
KR20150021993A (ko) 2015-03-03
PL3348553T3 (pl) 2021-02-08
TWI532732B (zh) 2016-05-11
LUC00236I2 (enExample) 2025-02-03
LT3533792T (lt) 2021-07-26
LT2858985T (lt) 2018-09-25
AU2013271751B2 (en) 2017-02-23
CN104619692A (zh) 2015-05-13
EP3348553B1 (en) 2020-07-08
SI2858985T1 (sl) 2018-12-31
ZA201500076B (en) 2016-10-26
CY1120393T1 (el) 2019-07-10
CR20140549A (es) 2015-04-06
FR21C1050I1 (fr) 2021-12-10
IL259738A (en) 2018-07-31
HRP20201387T1 (hr) 2020-11-27
CA3055660A1 (en) 2013-12-12
HK1210175A1 (en) 2016-04-15
US20210163441A1 (en) 2021-06-03
PL3533792T3 (pl) 2021-11-29
FR21C1050I2 (fr) 2024-05-24
US20190330182A1 (en) 2019-10-31
EP3922629A1 (en) 2021-12-15
EA033956B1 (ru) 2019-12-13
ES2670683T3 (es) 2018-05-31
HUE050357T2 (hu) 2020-11-30
PT2858985T (pt) 2018-07-10
US20170001977A1 (en) 2017-01-05
US20250092011A1 (en) 2025-03-20
ES2809738T3 (es) 2021-03-05
HK1226066A1 (zh) 2017-09-22
JP2018141009A (ja) 2018-09-13
CA3008345A1 (en) 2013-12-12
IL320522A (en) 2025-06-01
EA201992010A1 (ru) 2020-01-24
IN2014DN10084A (enExample) 2015-08-21
NZ702203A (en) 2016-09-30
UA123142C2 (uk) 2021-02-24
DK2858985T3 (en) 2018-05-28
CR20190331A (es) 2019-11-12
IL259738B (en) 2021-06-30
SG11201408140QA (en) 2015-01-29
AU2017200298B2 (en) 2017-09-28
GT201400283A (es) 2017-07-03
SI3533792T1 (sl) 2021-11-30
PT3348553T (pt) 2020-09-28
WO2013184681A1 (en) 2013-12-12
LTPA2021525I1 (enExample) 2021-11-25
CY2021032I1 (enExample) 2022-03-24
US10526310B2 (en) 2020-01-07
EP2858985B1 (en) 2018-04-18
NI201400142A (es) 2016-12-02
US10934271B2 (en) 2021-03-02
CN113135892A (zh) 2021-07-20
EA028791B1 (ru) 2017-12-29
JP2015518890A (ja) 2015-07-06
US20200354335A1 (en) 2020-11-12
HRP20180902T1 (hr) 2018-08-24
US20180258067A1 (en) 2018-09-13
CA2875767C (en) 2018-08-14
AU2017279807B2 (en) 2018-11-08
AU2017279807A1 (en) 2018-01-25
KR20190132543A (ko) 2019-11-27
ECSP14030098A (es) 2016-01-29
NZ717683A (en) 2018-04-27
AU2013271751A1 (en) 2014-12-18
ME03081B (me) 2019-01-20
CL2014003331A1 (es) 2016-03-04
JP6182209B2 (ja) 2017-08-16
IL236055A0 (en) 2015-02-01
PH12014502714A1 (en) 2015-02-02
JP6345821B2 (ja) 2018-06-20
CA3114726A1 (en) 2013-12-12
PH12014502714B1 (en) 2015-02-02
HRP20210909T1 (hr) 2021-09-03
US10556882B2 (en) 2020-02-11
SG10201610249TA (en) 2017-02-27
IL275413A (en) 2020-07-30
EA201791592A1 (ru) 2018-01-31
ES2875932T3 (es) 2021-11-11
PH12016501470B1 (en) 2021-12-10
BR112014030678A2 (pt) 2017-06-27
CA3008345C (en) 2019-10-22
IL267608B1 (en) 2025-06-01
CN105693692A (zh) 2016-06-22
EP3348553A1 (en) 2018-07-18
DK3348553T3 (da) 2020-07-27
US10766875B2 (en) 2020-09-08
PH12016501470A1 (en) 2017-07-10
ME03815B (me) 2021-04-20
US9994545B2 (en) 2018-06-12
PE20150631A1 (es) 2015-05-11
AU2017200298A1 (en) 2017-02-02
PL2858985T3 (pl) 2018-09-28
LTC3533792I2 (enExample) 2024-07-10
US10308630B2 (en) 2019-06-04
IL267608B2 (en) 2025-10-01
KR102062024B1 (ko) 2020-01-03
SMT202000496T1 (it) 2020-11-10
TR201808939T4 (tr) 2018-07-23
CO7240407A2 (es) 2015-04-17
DK3533792T3 (da) 2021-06-28
JP2017178923A (ja) 2017-10-05
LT3348553T (lt) 2020-09-25
CY1123427T1 (el) 2021-12-31
PT3533792T (pt) 2021-06-07
NO2021046I1 (no) 2021-11-02
SMT201800311T1 (it) 2018-07-17
US9481663B2 (en) 2016-11-01
RS57370B1 (sr) 2018-08-31
CY1124831T1 (el) 2022-03-24
UA115665C2 (uk) 2017-12-11
EP3533792B1 (en) 2021-05-05
SG10201610248SA (en) 2017-02-27
US20150133481A1 (en) 2015-05-14
EP2858985A4 (en) 2016-05-25
SMT202100355T1 (it) 2021-07-12
EP2858985A1 (en) 2015-04-15
HUS2100047I1 (hu) 2021-11-29
US20200115361A1 (en) 2020-04-16
CY2021032I2 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
NL301173I2 (nl) amivantamab
EP2763896A4 (en) UNMANUFACTURED AIRCRAFT WITH SEVERAL ROTORS
DK2859055T3 (da) Polymercoatings
EP2880683A4 (en) BVA INTERPOSER
DK2825087T3 (da) Otoscanner
EP2809145A4 (en) CHLOROPLAST TRANSIT PEPTIDES
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
EP2814472A4 (en) DITHIOAMINE REDUCING AGENTS
EP2824794A4 (en) Charging cable
EP2847405A4 (en) DOOR CLOSURE SYSTEM
EP2805877A4 (en) UNDER HOOD
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2873977T3 (da) Dobbeltdækker-rørdispenser
DK2854722T3 (da) Stomipose
EP2941099A4 (en) SWITCHING DEVICE
EP2831482A4 (en) Flange gasket
EP2816694A4 (en) FLAT CABLE WINDING DEVICE
DK2825157T3 (da) Aminosyrelipider
EP2809729A4 (en) Siloxane polyether copolymers
EP2862179A4 (en) FUEL CURRENT INSPECTION PROBE
EP2869113A4 (en) DISPLAY DEVICE FOR VEHICLE
EP2801315A4 (en) SCANNING ENDOSCOPE DEVICE
DE112012006214T8 (de) Wulstringwickler
DK2831122T3 (da) Anthocyanidin-kompleks
DK2885638T3 (da) Molekylenet